{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:28:44Z","timestamp":1740137324832,"version":"3.37.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["FAPESP: 2016\/25416-3"],"award-info":[{"award-number":["FAPESP: 2016\/25416-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["CAPES - Funding Code 001","CAPES - Funding Code 001"],"award-info":[{"award-number":["CAPES - Funding Code 001","CAPES - Funding Code 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s10238-021-00708-w","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T11:08:22Z","timestamp":1617966502000},"page":"587-597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inflammation response and liver stiffness: predictive model of regression of hepatic stiffness after sustained virological response in cirrhotics patients with chronic hepatitis C"],"prefix":"10.1007","volume":"21","author":[{"given":"Aline M\u00e1rcia Marques","family":"Braz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda Cristina","family":"Winckler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larissa Sarri","family":"Binelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Guilherme","family":"Chimeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lia Beatriz Mantovani","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo Santos","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael Plana","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rejane Maria Tommasini","family":"Grotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4824-9441","authenticated-orcid":false,"given":"Marjorie de Assis","family":"Golim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Faria","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"key":"708_CR1","doi-asserted-by":"publisher","unstructured":"Eisenhardt M, Gl\u00e4ssner A, Kr\u00e4mer B, et al. The CXCR3(+)CD56Bright phenotype characterizes a distinct NK cell subset with anti-fibrotic potential that shows dys-regulated activity in hepatitis C. Sandberg JK, editor. PLoS ONE. 2012;7: e38846. doi:https:\/\/doi.org\/10.1371\/journal.pone.0038846","DOI":"10.1371\/journal.pone.0038846"},{"key":"708_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jpg.2014.03.001","volume":"21","author":"J Anjo","year":"2014","unstructured":"Anjo J, Caf\u00e9 A, Carvalho A, et al. O impacto da hepatite C em Portugal. GE J Port Gastrenterol. 2014;21:44\u201354. https:\/\/doi.org\/10.1016\/j.jpg.2014.03.001.","journal-title":"GE J Port Gastrenterol"},{"key":"708_CR3","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/jvh.12578","volume":"23","author":"V Knop","year":"2016","unstructured":"Knop V, Hoppe D, Welzel T, et al. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. J Viral Hepat. 2016;23:994\u20131002. https:\/\/doi.org\/10.1111\/jvh.12578.","journal-title":"J Viral Hepat"},{"key":"708_CR4","doi-asserted-by":"publisher","unstructured":"Baskic D, Vukovic V, Popovic S, et al. Correction: chronic hepatitis C: conspectus of immunological events in the course of fibrosis evolution (PLoS ONE (2019)14:7 (e0219508). doi:https:\/\/doi.org\/10.1371\/journal.pone.0219508). PLoS ONE. 2019;14: 1\u201316. doi:https:\/\/doi.org\/10.1371\/journal.pone.0221142","DOI":"10.1371\/journal.pone.0219508 10.1371\/journal.pone.0221142"},{"key":"708_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1089\/vim.2018.0124","volume":"32","author":"M Irshad","year":"2019","unstructured":"Irshad M, Gupta P, Irshad K. Immunopathogenesis of liver injury during hepatitis C Virus infection. Viral Immunol. 2019;32:112\u201320. https:\/\/doi.org\/10.1089\/vim.2018.0124.","journal-title":"Viral Immunol"},{"key":"708_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1590\/0037-8682-0427-2017","volume":"52","author":"RMT Grotto","year":"2019","unstructured":"Grotto RMT, Santos FM, Picelli N, et al. HPA-1a\/1b could be considered a molecular predictor of poor prognosis in chronic hepatitis C. Rev Soc Bras Med Trop. 2019;52:2. https:\/\/doi.org\/10.1590\/0037-8682-0427-2017.","journal-title":"Rev Soc Bras Med Trop"},{"key":"708_CR7","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1189\/jlb.4mr0314-141r","volume":"96","author":"B Saha","year":"2014","unstructured":"Saha B, Szabo G. Innate immune cell networking in hepatitis C virus infection. J Leukoc Biol. 2014;96:757\u201366. https:\/\/doi.org\/10.1189\/jlb.4mr0314-141r.","journal-title":"J Leukoc Biol"},{"key":"708_CR8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/cells8030274","volume":"8","author":"T Patra","year":"2019","unstructured":"Patra T, Ray R, Ray R. Strategies to circumvent host innate immune response by hepatitis C virus. Cells. 2019;8:274. https:\/\/doi.org\/10.3390\/cells8030274.","journal-title":"Cells"},{"key":"708_CR9","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1172\/JCI66028.Fibrosis","volume":"123","author":"D Schuppan","year":"2013","unstructured":"Schuppan D, Kim YO. Review series: evolving therapies for liver fibrosis. J Clin Invest. 2013;123:1887\u2013901. https:\/\/doi.org\/10.1172\/JCI66028.Fibrosis.","journal-title":"J Clin Invest"},{"key":"708_CR10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3855\/jidc.7595","volume":"10","author":"A Alhetheel","year":"2016","unstructured":"Alhetheel A, Albarrag A, Shakoor Z, Alswat K, Abdo A, Al-Hamoudi W. Assessment of proinflammatory cytokines in sera of patients with hepatitis C virus infection before and after anti-viral therapy. J Infect Dev Ctries. 2016;10:1093\u20138. https:\/\/doi.org\/10.3855\/jidc.7595.","journal-title":"J Infect Dev Ctries"},{"key":"708_CR11","doi-asserted-by":"publisher","first-page":"001","DOI":"10.1055\/s-0036-1597816","volume":"37","author":"L Campana","year":"2017","unstructured":"Campana L, Iredale J. Regression of liver fibrosis. Semin Liver Dis. 2017;37:001\u201310. https:\/\/doi.org\/10.1055\/s-0036-1597816.","journal-title":"Semin Liver Dis"},{"key":"708_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5152\/tjg.2018.17330","volume":"29","author":"MM Aydin","year":"2018","unstructured":"Aydin MM, Akcali KC. Liver fibrosis. Turk J Gastroenterol. 2018;29:14\u201321. https:\/\/doi.org\/10.5152\/tjg.2018.17330.","journal-title":"Turk J Gastroenterol"},{"key":"708_CR13","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.cgh.2013.01.005","volume":"11","author":"DC Rockey","year":"2013","unstructured":"Rockey DC. Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies. Clin Gastroenterol Hepatol. 2013;11:224\u201331. https:\/\/doi.org\/10.1016\/j.cgh.2013.01.005.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"708_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5604\/16652681.1184193","volume":"15","author":"JF Quarleri","year":"2016","unstructured":"Quarleri JF, Oubi\u00f1a JR. Hepatitis c virus strategies to evade the specific-T cell response: a possible mission favoring its persistence. Ann Hepatol. 2016;15:17\u201326. https:\/\/doi.org\/10.5604\/16652681.1184193.","journal-title":"Ann Hepatol"},{"key":"708_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cyto.a.22348","volume":"85","author":"L Cosmi","year":"2014","unstructured":"Cosmi L, Maggi L, Santarlasci V, Liotta F, Annunziato F. T helper cells plasticity in inflammation. Cytom Part A. 2014;85:36\u201342. https:\/\/doi.org\/10.1002\/cyto.a.22348.","journal-title":"Cytom Part A"},{"key":"708_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3390\/cells7100165","volume":"7","author":"M Barathan","year":"2018","unstructured":"Barathan M, Mohamed R, Yong Y, Kannan M, Vadivelu J, Saeidi A, et al. Viral persistence and chronicity in hepatitis C virus infection: Role of T-cell apoptosis. Senescence Exhaust Cells. 2018;7:165. https:\/\/doi.org\/10.3390\/cells7100165.","journal-title":"Senescence Exhaust Cells"},{"key":"708_CR17","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00011-018-1174-3","volume":"67","author":"SM Poznanski","year":"2018","unstructured":"Poznanski SM, Barra NG, Ashkar AA, Schertzer JD. Immunometabolism of T cells and NK cells: metabolic control of effector and regulatory function. Inflamm Res. 2018;67:813\u201328. https:\/\/doi.org\/10.1007\/s00011-018-1174-3.","journal-title":"Inflamm Res"},{"key":"708_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00535-016-1258-1","volume":"52","author":"S Terai","year":"2017","unstructured":"Terai S, Tsuchiya A. Status of and candidates for cell therapy in liver cirrhosis: overcoming the \u201cpoint of no return\u201d in advanced liver cirrhosis. J Gastroenterol. 2017;52:129\u201340. https:\/\/doi.org\/10.1007\/s00535-016-1258-1.","journal-title":"J Gastroenterol"},{"key":"708_CR19","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1053\/gast.2002.33023","volume":"122","author":"T Poynard","year":"2002","unstructured":"Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303\u201313. https:\/\/doi.org\/10.1053\/gast.2002.33023.","journal-title":"Gastroenterology"},{"key":"708_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.bpg.2011.02.003","volume":"25","author":"L Castera","year":"2011","unstructured":"Castera L. Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Best Pract Res Clin Gastroenterol. 2011;25:291\u2013303. https:\/\/doi.org\/10.1016\/j.bpg.2011.02.003.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"2113\u20132120","key":"708_CR21","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.cgh.2014.04.037","volume":"12","author":"K Patel","year":"2014","unstructured":"Patel K, Remlinger KS, Walker TG, et al. Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2014;12(2113\u20132120):e3. https:\/\/doi.org\/10.1016\/j.cgh.2014.04.037.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"708_CR22","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1111\/jgh.14707","volume":"34","author":"FF Fernandes","year":"2019","unstructured":"Fernandes FF, Piedade J, Guimaraes L, et al. Effectiveness of direct-acting agents for hepatitis C and liver stiffness changing after sustained virological response. J Gastroenterol Hepatol. 2019;34:2187\u201395. https:\/\/doi.org\/10.1111\/jgh.14707.","journal-title":"J Gastroenterol Hepatol"},{"key":"708_CR23","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1097\/MEG.0000000000000964","volume":"29","author":"E Dolmazashvili","year":"2017","unstructured":"Dolmazashvili E, Abutidze A, Chkhartishvili N, Karchava M, Sharvadze L, Tsertsvadze T. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: Results of hepatology clinic HEPA exper. Eur J Gastroenterol Hepatol. 2017;29:1223\u201330. https:\/\/doi.org\/10.1097\/MEG.0000000000000964.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"708_CR24","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1148\/rg.2016160042","volume":"36","author":"A Srinivasa Babu","year":"2016","unstructured":"Srinivasa Babu A, Wells ML, Teytelboym OM, et al. Elastography in chronic liver disease: modalities, techniques, limitations, and future directions. Radiographics. 2016;36:1987\u20132006. https:\/\/doi.org\/10.1148\/rg.2016160042.","journal-title":"Radiographics"},{"key":"708_CR25","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.3748\/wjg.v20.i16.4787","volume":"20","author":"G Ferraioli","year":"2014","unstructured":"Ferraioli G, Tinelli C, Lissandrin R, et al. Point shear wave elastography method for assessing liver stiffness. World J Gastroenterol. 2014;20:4787\u201396. https:\/\/doi.org\/10.3748\/wjg.v20.i16.4787.","journal-title":"World J Gastroenterol"},{"key":"708_CR26","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1053\/j.gastro.2014.03.019","volume":"146","author":"JP Iredale","year":"2014","unstructured":"Iredale JP, Bataller R. Identifying molecular factors that contribute to resolution of liver fibrosis. Gastroenterology. 2014;146:1160\u20134. https:\/\/doi.org\/10.1053\/j.gastro.2014.03.019.","journal-title":"Gastroenterology"},{"key":"708_CR27","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry MP, O\u2019Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1512614.","journal-title":"N Engl J Med"},{"key":"708_CR28","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1590\/s0004-2803.201800000-76","volume":"55","author":"GF Silva","year":"2018","unstructured":"Silva GF, de Andrade VG, Moreira A. Waiting DAAs list mortality impact in HCV cirrhotic patients. Arq Gastroenterol. 2018;55:343\u20135. https:\/\/doi.org\/10.1590\/s0004-2803.201800000-76.","journal-title":"Arq Gastroenterol"},{"key":"708_CR29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1053\/jhep.1996.v24.pm0008690394","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996;24:289\u201393. https:\/\/doi.org\/10.1053\/jhep.1996.v24.pm0008690394.","journal-title":"Hepatology"},{"key":"708_CR30","doi-asserted-by":"publisher","unstructured":"Association for the Study of the Liver (EASL). Recommendations on treatment of hepatitis C. J Hepatol. 2018;69: 461\u2013511. doi:https:\/\/doi.org\/10.1016\/j.jhep.2018.03.026","DOI":"10.1016\/j.jhep.2018.03.026"},{"issue":"27\u201338","key":"708_CR31","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.cgh.2017.04.038","volume":"16","author":"S Singh","year":"2018","unstructured":"Singh S, Facciorusso A, Loomba R, Falck-Ytter YT. Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(27\u201338):e4. https:\/\/doi.org\/10.1016\/j.cgh.2017.04.038.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"708_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S + to analyze and compare ROC curves. BMC Bioinf. 2011;12:77. https:\/\/doi.org\/10.1186\/1471-2105-12-77.","journal-title":"BMC Bioinf"},{"key":"708_CR33","doi-asserted-by":"publisher","unstructured":"Witten IH, Frank E, Hall MA, Pal CJ. Data mining: practical machine learning tools and techniques. In: Fourth. Kaufmann M, editor. Elsevier; 2017. doi:https:\/\/doi.org\/10.1016\/C2015-0-02071-8","DOI":"10.1016\/C2015-0-02071-8"},{"key":"708_CR34","unstructured":"Chang J. Collapsed gibbs sampling methods for topic models. In: RDocumentation. Ida Package [Internet]. 2015. https:\/\/www.rdocumentation.org\/packages\/lda\/versions\/1.4.2. Acessed 2 Out 2020."},{"key":"708_CR35","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/hep4.1228","volume":"2","author":"JJ Pan","year":"2018","unstructured":"Pan JJ, Bao F, Du E, et al. Morphometry confirms fibrosis regression from sustained virologic response to direct-acting antivirals for hepatitis C. Hepatol Commun. 2018;2:1320\u201330. https:\/\/doi.org\/10.1002\/hep4.1228.","journal-title":"Hepatol Commun"},{"key":"708_CR36","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1093\/cid\/ciz359","volume":"70","author":"H Toyoda","year":"2020","unstructured":"Toyoda H, Tada T, Yasuda S, Mizuno K, Ito T, Kumada T. Dynamic evaluation of liver fibrosis to assess the risk of hepatocellular carcinoma in patients with chronic hepatitis C who achieved sustained virologic response. Clin Infect Dis. 2020;70:1208\u201314. https:\/\/doi.org\/10.1093\/cid\/ciz359.","journal-title":"Clin Infect Dis"},{"key":"708_CR37","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/hepr.13310","volume":"49","author":"R Yamada","year":"2019","unstructured":"Yamada R, Hiramatsu N, Oze T, et al. Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic response. Hepatol Res. 2019;49:570\u20138. https:\/\/doi.org\/10.1111\/hepr.13310.","journal-title":"Hepatol Res"},{"key":"708_CR38","doi-asserted-by":"publisher","first-page":"399","DOI":"10.7326\/0003-4819-149-6-200809160-00006","volume":"149","author":"V Mallet","year":"2008","unstructured":"Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med. 2008;149:399. https:\/\/doi.org\/10.7326\/0003-4819-149-6-200809160-00006.","journal-title":"Ann Intern Med"},{"key":"708_CR39","doi-asserted-by":"publisher","first-page":"64","DOI":"10.4254\/wjh.v9.i1.64","volume":"9","author":"T Suda","year":"2017","unstructured":"Suda T, Okawa O, Masaoka R, et al. Shear wave elastography in hepatitis C patients before and after antiviral therapy. World J Hepatol. 2017;9:64\u20138. https:\/\/doi.org\/10.4254\/wjh.v9.i1.64.","journal-title":"World J Hepatol"},{"key":"708_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0195173","volume":"13","author":"K Hamada","year":"2018","unstructured":"Hamada K, Saitoh S, Nishino N, et al. Shear wave elastography predicts hepatocellular carcinoma risk in hepatitis C patients after sustained virological response. PLoS ONE. 2018;13:1\u201311. https:\/\/doi.org\/10.1371\/journal.pone.0195173.","journal-title":"PLoS ONE"},{"key":"708_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/toxsci\/kfq134","volume":"117","author":"JM Tarrant","year":"2010","unstructured":"Tarrant JM. Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: considerations for their use. Toxicol Sci. 2010;117:4\u201316. https:\/\/doi.org\/10.1093\/toxsci\/kfq134.","journal-title":"Toxicol Sci"},{"key":"708_CR42","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12865-019-0313-0","volume":"20","author":"N Aziz","year":"2019","unstructured":"Aziz N, Detels R, Quint JJ, Gjertson D, Ryner T, Butch AW. Biological variation of immunological blood biomarkers in healthy individuals and quality goals for biomarker tests. BMC Immunol. 2019;20:2\u201311. https:\/\/doi.org\/10.1186\/s12865-019-0313-0.","journal-title":"BMC Immunol"},{"key":"708_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13777-3","author":"DA Rios","year":"2017","unstructured":"Rios DA, Valva P, Casciato PC, et al. Chronic hepatitis C liver microenvironment: role of the Th17\/Treg interplay related to fibrogenesis. Sci Rep. 2017. https:\/\/doi.org\/10.1038\/s41598-017-13777-3.","journal-title":"Sci Rep"},{"key":"708_CR44","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2174\/1871530319666181206125545","volume":"19","author":"MLH Medel","year":"2019","unstructured":"Medel MLH, Reyes GG, Porras LM, et al. Prolactin induces IL-2 associated TRAIL expression on natural killer cells from chronic hepatitis C patients in vivo and in vitro. Endocrine Metab Immune Disord Drug Targets. 2019;19:975\u201384. https:\/\/doi.org\/10.2174\/1871530319666181206125545.","journal-title":"Endocrine Metab Immune Disord Drug Targets"},{"key":"708_CR45","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1590\/0037-8682-0137-2018","volume":"51","author":"FC Winckler","year":"2018","unstructured":"Winckler FC, Braz AMM, da Silva VN, et al. Influence of the inflammatory response on treatment of hepatitis C with triple therapy. Rev Soc Bras Med Trop. 2018;51:731\u20136. https:\/\/doi.org\/10.1590\/0037-8682-0137-2018.","journal-title":"Rev Soc Bras Med Trop"},{"key":"708_CR46","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jhep.2016.12.019","volume":"66","author":"B Langhans","year":"2017","unstructured":"Langhans B, Nischalke HD, Kr\u00e4mer B, et al. Increased peripheral CD4+ regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C. J Hepatol. 2017;66:888\u201396. https:\/\/doi.org\/10.1016\/j.jhep.2016.12.019.","journal-title":"J Hepatol"},{"key":"708_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13027-016-0070-0","volume":"11","author":"SF Abdelwahab","year":"2016","unstructured":"Abdelwahab SF. Cellular immune response to hepatitis-C-virus in subjects without viremia or seroconversion: Is it important? Infect Agent Cancer. 2016;11:1\u201312. https:\/\/doi.org\/10.1186\/s13027-016-0070-0.","journal-title":"Infect Agent Cancer"},{"key":"708_CR48","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/eji.201444903","volume":"45","author":"RA De Groen","year":"2015","unstructured":"De Groen RA, Boltjes A, Hou J, et al. IFN-\u03bb-mediated IL-12 production in macrophages induces IFN-\u03b3 production in human NK cells. Eur J Immunol. 2015;45:250\u20139. https:\/\/doi.org\/10.1002\/eji.201444903.","journal-title":"Eur J Immunol"},{"key":"708_CR49","doi-asserted-by":"publisher","first-page":"e0175793","DOI":"10.1371\/journal.pone.0175793","volume":"12","author":"CM Yang","year":"2017","unstructured":"Yang CM, Yoon JC, Park JH, Lee JM. Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3. PLoS ONE. 2017;12:e0175793. https:\/\/doi.org\/10.1371\/journal.pone.0175793.","journal-title":"PLoS ONE"},{"key":"708_CR50","doi-asserted-by":"publisher","first-page":"e95614","DOI":"10.1371\/journal.pone.0095614","volume":"9","author":"E Fugier","year":"2014","unstructured":"Fugier E, Marche H, Th\u00e9lu MA, et al. Functions of liver natural killer cells are dependent on the severity of liver inflammation and fibrosis in chronic hepatitis C. PLoS ONE. 2014;9:e95614. https:\/\/doi.org\/10.1371\/journal.pone.0095614.","journal-title":"PLoS ONE"},{"key":"708_CR51","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ijid.2020.04.041","volume":"95","author":"Z Zhu","year":"2020","unstructured":"Zhu Z, Cai T, Fan L, et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. Int J Infect Dis. 2020;95:332\u20139. https:\/\/doi.org\/10.1016\/j.ijid.2020.04.041.","journal-title":"Int J Infect Dis"},{"key":"708_CR52","doi-asserted-by":"publisher","unstructured":"Da Silva Neto PV, Carvalho JCS, Pimentel VE, et al. Prognostic value of sTREM-1 in COVID-19 patients: a biomarker 1 for disease severity and mortality Corresponding: 40. medRxiv. 2020; 1\u201328. doi:https:\/\/doi.org\/10.1101\/2020.09.22.20199703","DOI":"10.1101\/2020.09.22.20199703"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-021-00708-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-021-00708-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-021-00708-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T10:06:39Z","timestamp":1634033199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-021-00708-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["708"],"URL":"https:\/\/doi.org\/10.1007\/s10238-021-00708-w","relation":{},"ISSN":["1591-8890","1591-9528"],"issn-type":[{"type":"print","value":"1591-8890"},{"type":"electronic","value":"1591-9528"}],"subject":[],"published":{"date-parts":[[2021,4,9]]},"assertion":[{"value":"18 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no competing interests exist.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Research Ethics Committee of Botucatu Medical School, UNESP (protocol no. 2.810.759).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All the included patients signed the informed consent form.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data here presented are available to consult with the corresponding author.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}